& Kaufman, H
Abstract Enteroendocrine L-cell derived peptide hormones, notably glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2), have become important targets in the treatment of type 2 diabetes, obesity and intestinal diseases
Adding Wegovy, another weight-loss medication, would mean using three different drugs
This is why a targeted approach is so important
When retatrutide enters the picture, outcomes tend to feel more consistent
Right now, our biggest challenge is that theyre not necessarily convinced that by investing up front in these medications to treat obesity upstream, it will offset the cost of treating the medical conditions related to weight downstream. According to Novo Nordisk, about 50 million Americans with obesity should be able to access Wegovy through insurance